Mutational activation of BRAF is a frequent event in human malignant melanomas suggesting that BRAFdependent signaling is conducive to melanoma cell growth and survival. Previously published work reported that melanoma cells exhibit constitutive anti-apoptotic nuclear factor jB (NF-jB) transcription factor activation triggered by proteolysis of its inhibitor IjB. IjB degradation is dependent upon its phosphorylation by the IjB kinase (IKK) complex and subsequent ubiquitination facilitated by b-Trcp E3 ubiquitin ligase. Here, we report that melanocytes expressing a conditionally oncogenic form of BRAF V600E exhibit enhanced b-Trcp expression, increased IKK activity and a concomitant increase in the rate of IjBa degradation. Conversely, inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor or by selective knock-down of BRAF V600E expression by RNA interference in human melanoma cells leads to decreased IKK activity and b-Trcp expression, stabilization of IjB, inhibition of NF-jB transcriptional activity and sensitization of these cells to apoptosis. Taken together, these data support a model in which mutational activation of BRAF in human melanomas contributes to constitutive induction of NF-jB activity and to increased survival of melanoma cells.
Mutational activation of BRAF is a frequent event in human malignant melanomas suggesting that BRAFdependent signaling is conducive to melanoma cell growth and survival. Previously published work reported that melanoma cells exhibit constitutive anti-apoptotic nuclear factor jB (NF-jB) transcription factor activation triggered by proteolysis of its inhibitor IjB. IjB degradation is dependent upon its phosphorylation by the IjB kinase (IKK) complex and subsequent ubiquitination facilitated by b-Trcp E3 ubiquitin ligase. Here, we report that melanocytes expressing a conditionally oncogenic form of BRAF V600E exhibit enhanced b-Trcp expression, increased IKK activity and a concomitant increase in the rate of IjBa degradation. Conversely, inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor or by selective knock-down of BRAF V600E expression by RNA interference in human melanoma cells leads to decreased IKK activity and b-Trcp expression, stabilization of IjB, inhibition of NF-jB transcriptional activity and sensitization of these cells to apoptosis. Taken together, these data support a model in which mutational activation of BRAF in human melanomas contributes to constitutive induction of NF-jB activity and to increased survival of melanoma cells. Oncogene (2007 Oncogene ( ) 26, 1954 Oncogene ( -1958 Oncogene ( . doi:10.1038 published online 25 September 2006 Keywords: BRAF; melanoma; b-Trcp; NF-kB; IkB kinase Malignant melanoma is the most lethal skin cancer, whose ability to rapidly metastasize often prevents surgical cure. Furthermore, the systemic treatment of melanoma is largely ineffective due to the intrinsic resistance of melanoma cells to numerous anticancer agents. Increased survival of melanoma cells is primarily attributed to the constitutive activation of the transcription factor nuclear factor kB (NF-kB), which regulates the expression of many anti-apoptotic, pro-proliferative and pro-metastatic genes (Amiri and Richmond, 2005; Ueda and Richmond, 2006) . Canonical activation of the NF-kB pathway occurs when NF-kB switches its localization from the cytoplasm, where it is maintained inactive by assembly with the inhibitor IkB protein, to the nucleus, where NF-kB regulates gene expression. NF-kB activation relies upon the phosphorylationdependent ubiquitination and degradation of IkB mediated by the IkB kinase (IKK) complex and b-Trcp E3 ubiquitin ligases (reviewed by Karin and Ben-Neriah, 2000) . Consequently, both IKK activity and the levels of b-Trcp regulate the extent of IkB degradation and hence NF-kB activation (Fuchs et al., 2004) .
The genetic basis that underlies the elevated NF-kB activity in malignant melanoma largely remains elusive. Constitutively active IKK has been demonstrated to sustain NF-kB activation in human melanoma cells, resulting in induction of the chemokine CXCL1. CXCL1, in turn, is capable of activating IKK and NF-kB and promoting cell survival and tumorigenesis (Yang and Richmond, 2001 ). However, the original genetic alterations that initiate this feed-forward mechanism in melanoma remain unclear. One of the major oncogenic events described in the genesis of malignant melanoma is constitutive activation of the Ras-regulated RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway. This is achieved most frequently by activating mutations in either BRAF (e.g. V600E substitution) or, less frequently, in N-RAS (reviewed by Smalley, 2003; Smalley and Herlyn, 2005) . Recent evidence indicates that oncogenic BRAF activity is essential for human melanoma cell growth and survival (Hoeflich et al., 2006) . However, despite prior reports that RAF can activate NF-kB (Norris and Baldwin, 1999) , the mechanism(s) by which BRAF V600E (BRAF VE ) may elicit NF-kB signaling in melanoma cells have not yet been elucidated.
Activation of the canonical NF-kB pathway depends on both IKK activity, which has been shown to be elevated in human melanomas (Amiri and Richmond, 2005; Ueda and Richmond, 2006) , and the levels of b-Trcp, which functions as the substrate recognition subunit of the E3 ubiquitin ligase that facilitates IkB ubiquitination (Fuchs et al., 2004) . Previously, we reported that b-Trcp2 mRNA and protein levels are induced by the mitogenic stimuli via the ERK MAPK pathway in a transcription-dependent manner in fibroblasts and myocytes (Spiegelman et al., 2002a) . Here, we examined the levels of b-Trcp in human melanoma cell lines that often harbor either BRAF or N-RAS mutations and were reported to exhibit the constitutive activation of the ERK MAPK pathway (Satyamoorthy et al., 2003) . As shown in Figure 1a , most of the melanoma cell lines express higher levels of b-Trcp than normal human melanocytes. To determine whether the expression of oncogenic BRAF VE leads to induction of b-Trcp, we employed Melan-A mouse melanocytes that stably express a BRAF VE :ER T2 fusion protein ( In order to exclude that effects of activated BRAF in melanocytes might be attributed solely to its overexpression, we next determined whether inhibition of BRAF VE -MEK-ERK signaling in human melanoma cells that harbor an activated allele of BRAF may affect b-Trcp expression. To this end, we used pharmacologic inhibitors as well as the RNA interference approach to knock down the oncogenic BRAF VE . Both treatments decreased the activity of a b-Trcp2 promoter-driven luciferase reporter in human melanoma cells (data not shown), which was reported earlier to be stimulated by mitogenic stimuli including viral Ras (Spiegelman et al., 2002a) . Treatment of 1205Lu human melanoma cells with either an inhibitor of Raf kinases (BAY 43-9006, Figure 1e ) or with specific MEK1 inhibitors (U0126, Figure 1e or PD 098059, data not shown) reduced both constitutive ERK activation and the levels of b-Trcp expression. In addition, transfection of 1205Lu melanoma cells with an small hairpin RNA (shRNA) construct that specifically suppresses expression of the BRAF VE mutant allele without affecting wild-type BRAF (Hingorani et al. 2003 ; Figure 1e , lower panel) led to decreased ERK activation and expression of b-Trcp (Figure 1e ). Taken together, these data provide both pharmacologic and genetic evidence that oncogenic BRAF VE -mediated activation of the MAPK pathway contributes to the maintenance of b-Trcp expression in human melanoma cells.
As modulation of b-Trcp levels affects the rate of proteolytic turnover of its phosphorylated substrates (Fuchs et al., 2004) , we sought to determine whether the expression of oncogenic BRAF affects the stability of IkBa. Previous reports indicated that forced expression of BRAF mutants in COS and NIH 3T3 cells leads to NF-kB activation, which parallels the activation of ERK and which can be inhibited by non-degradable IkB super-repressor (Ikenoue et al., 2003 (Ikenoue et al., , 2004 . Pretreatment of Melan-A cells that harbor the BRAF VE :ER T2 fusion protein with 4-OHT led to an accelerated degradation of IkBa (measured by a cycloheximide (CHX) chase) that was not seen in parental mouse Melan-A cells (Figure 2a) . Remarkably, this increased IkBa turnover, which occurred concomitantly with increased ERK activation, was observed in cells that were not treated with known activators of IKK, such as tumor necrosis factor alpha (TNFa). Given that b-Trcpdriven ubiquitination depends on IkB phosphorylation by IKK, we next investigated the effect of oncogenic BRAF VE activation on the activation status of endogenous IKK. As shown in Figure 2b , activation of BRAF VE :ER T2 led to an increase in IKK activity, Induction of NF-jB by BRAF J Liu et al measured by an immunokinase assay using GST-IkBa as a substrate. Importantly, treatment of oncogenic BRAF-containing melanocytes with MEK1 inhibitor U0126 attenuated the increase in both IKK catalytic activity ( Figure 2c ) and kB luciferase reporter activity (Figure 2d ), indicating that the effects of BRAF are mediated by the MAPK pathway. In all, these results implicate oncogenic BRAF in the accelerated degradation of IkBa and activation of NF-kB; the former event is in turn likely to be stimulated by both IKK activation and b-Trcp induction.
These conclusions were further supported by the observation that treatment of 1205Lu human melanoma cells with BAY 43-9006 led to a marked decrease in the efficiency of IkBa turnover (Figure 3a ) and the activity of the endogenous IKK complex (Figure 3b ). In addition, the degradation of coexpressed Flag-tagged IkBa was dramatically impaired in these cells transfected with shRNA against BRAF VE (Figure 3c ). Furthermore, a moderate decrease in the activity of coexpressed Flagtagged IKKb was observed upon knock-down of oncogenic BRAF (Figure 3d) . A limited extent of inhibition here can be attributed to the findings that, under the conditions of overexpression, IKKb activity is partly independent of upstream signaling events (Zandi et al., 1997) . These data suggest that oncogenic BRAF VE -dependent signaling contributes to constitutive IKK activity and IkB degradation in human melanoma cells.
Given that IkB stability is regulated by BRAF, we predicted that signaling initiated by oncogenic BRAF should play an important role in the maintenance of constitutive NF-kB activity and perhaps, affect the survival of melanoma cells. Consistent with this hypothesis, we indeed found that inhibition of BRAF VE by either mutant-specific shRNA construct or treatment of melanoma cells with BAY 43-9006 resulted in decreased NF-kB transcriptional activity, measured by kB-driven luciferase reporter (Figure 4a) . A similar inhibition of NF-kB activity was achieved by treating the cells with U0126 inhibitor (Figure 4a ), indicating that oncogenic BRAF is likely to maintain the constitutive NF-kB activity via the MAPK pathway in human melanoma cells. This mode of regulation is dissimilar to MEK1-independent activation of NF-kB by viral mutant RAF in Jurkat cells (Baumann et al., 2000) .
To determine the functional significance of oncogenic BRAF-dependent maintenance of basal NF-kB activity in human melanoma cells, we assessed the rate of apoptosis in these cells using an experimental model in which we combined treatment with TNFa and CHX. Under these conditions (which were shown to induce apoptosis in melanoma cells in a b-Trcp activitydependent manner; Soldatenkov et al., 1999) TNFainducible NF-kB activation does not upregulate the Induction of NF-jB by BRAF J Liu et al anti-apoptotic proteins because protein synthesis is inhibited by CHX. Hence, the basal NF-kB activity that exists in cells before treatment determines their resistance to apoptosis. Pretreatment of 1205Lu human melanoma cells with BAY 43-9006 led to a significant increase in the number of apoptotic cells (Figure 4b ). These data are consistent with the recently demonstrated apoptotic effects of prolonged treatment with BAY 43-9006 (Panka et al., 2006) and with regression in cell and tumor growth upon RNAi-mediated knock-down of BRAF (Sharma et al., 2005; Hoeflich et al., 2006) . They also indicate that mutationally activated BRAF plays an important role in the survival of melanoma cells. Evidence presented herein strongly suggests that oncogenic BRAF plays an important role in the maintenance of constitutive NF-kB activity in human melanoma cells as well as in their survival. These results are in agreement with the data obtained from forced expression of BRAF mutants in COS or NIH 3T3 cells (Ikenoue et al., 2003 (Ikenoue et al., , 2004 . Given that BRAF mutations tend to occur early in melanomogenesis and are often found in benign nevi (reviewed by Smalley, 2003; Smalley and Herlyn, 2005) , it is tempting to speculate about the role of oncogenic BRAF-mediated NF-kB induction in the progression of malignant melanoma. Furthermore, BRAF inhibitors that decrease NF-kB activity might be useful adjuvants for combined chemotherapy of human melanoma. Indeed, one IKK inhibitor has already demonstrated dramatic efficacy against melanoma cells in pre-clinical settings (Yang et al., 2006) .
Early results of clinical trials on monotherapy with BAY 43-9006 (Sorafenib) in human melanoma suggested that it should be combined with other anticancer agents (Smalley and Herlyn, 2005) . Whereas BAY 43-9006 was shown to downregulate the expression of Bcl-X L (an NF-kB target protein), the mechanisms by which this agent promotes apoptosis in human melanoma cells are complex (Panka et al., 2006) and cannot be attributed solely to NF-kB inhibition. Future basic and translational research efforts are warranted to delineate additional mechanisms by which inhibition of oncogenic BRAF, on the one hand, and effects of available Raf and IKK inhibitors, on the other hand, mediate melanoma cell death and tumor regression. A comprehensive understanding of the mechanisms regulated by oncogenic BRAF will be required to optimize the therapeutic effects of combined therapy against malignant melanomas. Induction of NF-jB by BRAF J Liu et al
